(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today responding to another incomplete and unbalanced article from The New York Times, that again made sweeping assertions about pharmacy benefit managers (PBMs), this time distorting the
Thanks for contacting us! We will get in touch with you shortly.
Unlocking an Affordable Future: Key #1 Ensure System Sustainability ENSURE SYSTEM SUSTAINABILITY BY PROMOTING COMPETITION A competitive private market is the best way to manage drug costs. Interventions should be focused on fixing specific market failures or gaps rather than
America’s employers are increasingly highlighting the value that pharmacy benefit managers (PBMs) provide as critical partners in providing affordable, high-quality health care benefits for their employees. Business leaders from across the country are voicing their concerns with misguided proposals targeting
To help facilitate access to our nation’s nearly 70,000 retail pharmacies, PBMs are actively providing information to RxOpen, a central hub created after Hurricane Katrina to help promote uniform, consistent supply-chain information for stakeholders. PBMs also are supporting policy
A wide array of voices from across the country are calling on lawmakers to oppose recently reintroduced legislation, the Pharmacy Benefit Manager Transparency Act (S.127), which fundamentally misconstrues the role of pharmacy benefit companies, unfairly proposes to take away employers’
In case you missed it, WTOP’s Mitchell Miller spoke with former U.S. Senator Pat Toomey (R-PA) about the current health care debate in Congress in a conversation titled; “The Political And Economic Ramifications Of Undermining The Free Market In Health
Conversation on “Improving Competition to Lower Drug Prices” Emphasizes Need to Stop Abuse of the Patent System Last week, The Hill hosted an event titled, “Prescription for Change: Improving Competition to Lower Drug Prices.” During the event, lawmakers and a panel of drug
The U.S. House of Representatives is preparing a suspension vote on the Lower Costs, More Transparency Act, which includes many of the controversial, overreaching proposals impacting pharmacy benefits. A recent Washington Examiner article highlighted growing concerns among Members of Congress
©2024 PCMA. All Rights Reserved.
